Tibotec Pharmaceuticals, Ireland

Quick facts

Marketed products

• Ribavirin (R) · Virology/Infectious Disease
  Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.
• TMC278 · Other

Phase 3 pipeline

• Darunavir (DRV) · Infectious Disease
  Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
• TMC-114/RTV · Infectious diseases
  TMC-114/RTV is a protease inhibitor used in the treatment of HIV-1 infection.
• TMC114 · Infectious Diseases
  TMC114 is a protease inhibitor used to treat HIV-1 infection.
• TMC114/rtv · Infectious disease
  TMC114/rtv is a protease inhibitor used to treat HIV infection.
• TMC125 · Infectious Disease
  TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication.
• TMC435 · Infectious Diseases
  TMC435 is a protease inhibitor used to treat HIV-1 infection.

Phase 2 pipeline

• TMC-114
• TMC114; darunavir; Prezista

Phase 1 pipeline

• Etravirine; Lopinavir; Ritonavir
• Ovysmen · Other
• TMC114; TMC41629
• TMC278; Moxifloxacin; Efavirenz
• TMC278; Omeprazole
• TMC435 gelatin capsule
• TMC435 HPMC capsule
• TMC435 HPMC or gelatin capsule
• TMC435350

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tibotec Pharmaceuticals, Ireland portfolio CI brief
• Tibotec Pharmaceuticals, Ireland pipeline updates RSS